BIAF.NASDAQBioaffinity Technologies, INC

DEFA14A: bioAffinity Technologies Files Definitive Proxy Statement with SEC

Sentiment:

Definitive Proxy Statement

📋All filings for Bioaffinity Technologies, INC
🔒Login to Follow

bioAffinity Technologies, Inc. has filed a Definitive Proxy Statement (Schedule 14A) with the U.S. Securities and Exchange Commission.

Summary

  • The document is identified as a Definitive Proxy Statement (Schedule 14A) filed under Rule 14a-101 of the Securities Exchange Act of 1934.
  • The filing was made by bioAffinity Technologies, Inc., the Registrant, with the U.S. Securities and Exchange Commission.
  • The filing indicates options for the payment of filing fees, including 'No fee required', 'Fee paid previously with preliminary materials', or 'Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11'.

Sentiment

Score: 5

Explanation: The document is a standard procedural SEC filing (Definitive Proxy Statement cover page) and contains no substantive information to indicate positive or negative sentiment regarding company performance or outlook.

Future Outlook

NA

Industry Context

NA

Keywords

bioAffinity Technologies, SEC filing, DEFA14A, Proxy Statement, Corporate Governance

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.